Cellular and viral determinants of the persistent HIV reservoir

持久性艾滋病毒储存库的细胞和病毒决定因素

• 批准号: 10251431
• 负责人: Nadejda S Beliakova-Bethell
• 金额: --
• 依托单位: VA SAN DIEGO HEALTHCARE SYSTEM
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-10-01 至 2025-09-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10251431
• 关键词: Address; Adherence; Antibodies; Biological Assay; Biological Markers; Biological Specimen Banks; Blood; Blood specimen; CCR5 gene; CD4 Positive T Lymphocytes; CXCR4 gene; Cell model; Cells; Centers for Disease Control and Prevention (U.S.); Chronic; Clinical; Collaborations; Coupled; DNA; Data; Development; Diagnosis; Enrollment; Ensure; Flow Cytometry; Future; Gene Expression; Genes; Genetic Transcription; Gifts; Goals; HIV; HIV Infections; Healthcare Systems; Heterogeneity; Human body; Immunophenotyping; In Vitro; Individual; Infection; Length; Lymphoid Tissue; Membrane Proteins; Memory; Outcome; Pathway interactions; Patients; Persons; Phenotype; Population; Proteins; Proviruses; RNA; RNA Splicing; Research; Sampling; Stimulus; T-Lymphocyte; T-Lymphocyte Subsets; Technology; Testing; Tissue Sample; Tissues; Toxic effect; Transcript; Translating; Tropism; United States; Variant; Veterans; Viral; Virus; antiretroviral therapy; base; biomarker identification; cell type; cohort; cost; design; experimental study; genetic signature; improved; in vivo; innovation; latent HIV reservoir; protein biomarkers; purge; response; single-cell RNA sequencing; transcriptome sequencing; transcriptomics; viral rebound

Eradication of the latent HIV reservoir remains the major stumbling block to achieving cure. To eliminate this reservoir, accurate definition (a biomarker) of latently infected cells of different types and within different tissues is highly needed. Several biomarkers proposed previously were able to very modestly enrich (~10-fold) for latently infected cells, but failed to capture the substantial portion of the latent reservoir. Without the detailed characterization of latently infected cells, identification of a suitable biomarker to capture the majority of the reservoir cells will remain challenging. Our long-term goal is to identify a biomarker of HIV latency that can be translated into strategies to target latently infected cells for elimination. The overall objectives of this application are to identify cellular and viral determinants of the persistent HIV reservoir and to test selected biomarkers for their ability to capture latently infected cells in vitro and ex vivo. Our central hypothesis is that a successful biomarker will be represented by reservoir determinants identified individually for cells of different phenotypes and states. The term “phenotype” refers to the canonical phenotypic subsets defined with widely used surface protein markers (for example, maturation phenotype – central memory; functional phenotype – T helper 17). The term “state” refers to a cell state more broadly defined by the cell's total transcriptomic signature: gene sets and pathways that are actively expressed. The rationale of the proposed research is the expected improvement in the efficiency of the reservoir capture when heterogeneity of the reservoir cells is taken into account. We will test our central hypothesis by pursuing the following specific aims: (1) Identify cellular determinants of different reservoir subsets and test selected biomarkers for cell enrichment in vitro; (2) Identify viral determinants of different reservoir subsets in vitro; (3) Validate the reservoir determinants and selected biomarkers using samples from people with HIV. To identify cellular and viral determinants of the persistent reservoir, latest innovations in RNA sequencing (RNA-Seq) technologies will be used. Single cell RNA-Seq coupled with immunophenotyping will be used to characterize the phenotypes and states of cells that can be infected with either CXCR4- or CCR5-tropic virus. Genes that can discriminate between latently infected and uninfected cells will be identified individually within each cell type. To inform on how the identified cellular determinants of the persistent reservoir relate to the type of provirus that they define, proviral activity in different cell types will be characterized using single cell RNA-Seq data, full length sequencing of HIV transcripts, and the PrimeFlow assay to quantify responsiveness of provirus to reactivation stimuli. Biomarkers will be selected from sets of cellular determinants of the HIV reservoir in different cell subsets. Antibodies against these proteins will be tested for the ability to efficiently capture the latently infected cells. Our ultimate goal is to ensure that identified biomarkers can accurately define latently infected cells in clinical samples, and specifically in different tissue compartments, where as much as 98% of the persistent reservoir resides in vivo. In collaboration with the Last Gift cohort, we will have a unique opportunity to conduct studies to validate the identified determinants and biomarkers using blood and lymphoid tissue samples from persons with HIV. When these studies are complete, we will have identified biomarkers that can be used to capture latently infected cells in vitro and ex vivo, with the efficiency of at least 500-fold greater than is currently achievable. These results will be significant because identified biomarkers can be used to isolate reservoir cells from different tissues to provide better characterization of the latent reservoir across the human body. In the future, these biomarkers can serve as a platform for development of strategies to target latently infected cells for elimination. Such research is important to address the needs of people living with HIV, including the large cohort of HIV- infected patients within the national VA Healthcare System.

根除潜伏的艾滋病毒储存库仍然是实现治愈的主要障碍。为了消除这个